GILD 2Q19 HCV sales=$842M—including an $80M true-up adjustment in EU not related to actual sales in 2Q19. US HCV sales were $355M, and ex-US HCV sales $487M (including the $80M adjustment mentioned above).
Excluding the $80M true-up adjustment, 2Q19 HCV sales were $762M, -7% QoQ/-24% YoY.
Market Data 
Markets 
AI
